ME

ME

USD

23andMe Holding Co. Class A Common Stock

$0.606-0.142 (-18.944%)

실시간 가격

Healthcare
Diagnostics & Research
미국

가격 차트

차트 데이터 없음

핵심 지표

시장 지표
기업 기본 정보
거래 통계

시장 지표

시가

$0.748

고가

$0.606

저가

$0.606

거래량

N/A

기업 기본 정보

시가총액

13.3M

산업

Diagnostics & Research

국가

United States

거래 통계

평균 거래량

4.10M

거래소

NCM

통화

USD

52주 범위

저가 $0.48현재가 $0.606고가 $12.76

AI 분석 리포트

마지막 업데이트: 2025년 4월 23일
AI 생성데이터 소스: Yahoo Finance, Bloomberg, SEC

ME (23andMe Holding Co. Class A Common Stock): Analyzing Recent Turmoil & What It Means

Stock Symbol: ME Generate Date: 2025-04-23 12:33:05

Alright, let's take a look at what's been happening with 23andMe, ticker symbol ME. The past month or so has been pretty wild, and honestly, not in a good way for shareholders.

Recent News Buzz: A Tough Time

The news flow around 23andMe lately has been overwhelmingly negative. The biggest headline, by far, is the company filing for Chapter 11 bankruptcy protection back in late March. This is a massive deal; it means the company is restructuring its debts under court supervision, often with the goal of selling off assets or the whole business.

We've seen reports confirming this bankruptcy filing from multiple sources. The company itself announced it was starting a "voluntary Chapter 11 process" to try and sell itself and sort out its liabilities. Right around the same time, the CEO, Anne Wojcicki, stepped down from that role (though she's staying on the board).

Adding to the drama, one of the company's co-founders reportedly lashed out, criticizing the CEO and the board's oversight leading up to this point. Plus, there's been a lot of noise about data privacy, with the New York Attorney General even urging users to delete their genetic data now that the company is in bankruptcy and its database could potentially change hands.

So, the general feeling from the news? It's grim. Bankruptcy, leadership changes, and data concerns paint a very challenging picture. There was one piece about a new genetic report launched just before the bankruptcy news hit, but that positive development is completely overshadowed by the financial distress.

Checking the Price Chart: A Nosedive

Looking at the stock price over the last month or two tells the story pretty clearly. The price was bouncing around between $1.50 and $2.00 for a while. Then, right when all that bankruptcy news broke in late March, the stock took a massive dive. It plummeted from around $1.75 down to well under a dollar in just a couple of days.

Since that initial crash, the price has been incredibly volatile. We saw some huge spikes in trading volume, especially on March 27th, which often happens during major events like this as people react quickly. The price has bounced around quite a bit since the low point, but it's still trading at a fraction of where it was before the bankruptcy filing. The overall trend from the start of the year is sharply downwards, with that late-March drop being the defining event. The last recorded price in the data is around $1.27.

What the AI Models Say: Mixed Signals

The AI predictions for the very near term (today and the next couple of days) suggest relatively small price movements – a tiny gain today, a small gain tomorrow, and a small dip the day after. These are minor percentage changes, which might just reflect the stock settling into a volatile range after the big news.

The AI recommendation data is a bit contradictory, which isn't uncommon in complex situations like bankruptcy. It flags some bearish technical signs like the price being below a key moving average and a bearish MACD crossover, suggesting downward pressure. It also notes high volatility and small market cap as risks. On the other hand, it mentions things like KDJ suggesting oversold conditions and a surge in trading volume (which, in this case, is likely tied to the bankruptcy reaction, not necessarily strong buying conviction). It even mentions a potential target price that seems completely out of sync with the current situation and the bankruptcy reality. Given the fundamental news, relying heavily on these technical or potentially outdated fundamental AI points seems risky.

Putting It All Together: The Outlook

Based on the news, the price action, and even the cautious AI signals, the situation for ME stock looks extremely challenging. The bankruptcy filing is the dominant factor here. For shareholders, bankruptcy proceedings often mean that the value of common stock is significantly reduced, or even wiped out entirely, as creditors get paid before equity holders.

The sharp drop in the stock price directly reflects the market's reaction to this severe financial distress. While the price has bounced a bit off its absolute lows, the fundamental picture remains dire.

Thinking About Strategy: Extreme Caution

Given that the company has filed for bankruptcy and is looking to sell itself, the risk for investors is exceptionally high.

  • For those holding shares: The primary concern is the potential for significant or total loss of investment depending on the outcome of the bankruptcy proceedings and any potential sale.
  • For those considering buying: This is an extremely speculative situation. While sometimes stocks in bankruptcy can see volatile swings, the fundamental risk of the stock becoming worthless is very real and high. Suggesting specific entry points is difficult and risky in this context. Any potential "strategy" here would involve understanding and accepting the very high probability of losing most or all of the investment. It's not a typical investment scenario.

A Bit About the Company

Just to recap, 23andMe is in the genetics testing and therapeutics business. The key piece of information right now is that they filed for Chapter 11 bankruptcy on March 23, 2025, and are planning a court-supervised sale process. This completely changes the investment landscape for the stock.


Important Note: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Investing in stocks, especially companies undergoing bankruptcy proceedings, is highly speculative and involves significant risk, including the potential loss of your entire investment. Always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

관련 뉴스

GlobeNewswire

23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law

SAN FRANCISCO, March 26, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (NASDAQ:ME), a leading human genetics and biotechnology company, today announced that it has received approvals from

더 보기
23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law
CNBC

23andMe co-founder lashes out at CEO Wojcicki after bankruptcy filing, says board lacked oversight

23andMe co-founder Linda Avey expressed frustration about the fall of the genetics testing company in a social media post.

더 보기
23andMe co-founder lashes out at CEO Wojcicki after bankruptcy filing, says board lacked oversight
CNBC

With 23andMe entering bankruptcy, here's how to delete your genetic data

Now that 23andMe has filed for bankruptcy, another company could take control of its genetic database.

더 보기
With 23andMe entering bankruptcy, here's how to delete your genetic data
Reuters

New York Attorney General urges 23andMe users to delete their data

New York Attorney General Letitia James urged customers of 23andMe on Tuesday to delete their accounts and protect their data after the DNA-testing company filed for bankruptcy over the weekend.

더 보기
New York Attorney General urges 23andMe users to delete their data
Reuters

23andMe's journey from DNA testing pioneer to bankruptcy

23andMe filed for bankruptcy on Sunday, hit by faltering demand for its ancestry testing kits as it struggled to contain the reputational damage from a widespread data breach.

더 보기
23andMe's journey from DNA testing pioneer to bankruptcy
CNBC

23andMe files for bankruptcy, Anne Wojcicki steps down as CEO

Anne Wojcicki has resigned from her role as chief executive effective immediately, though she will remain a member of the board.

Reuters

DNA testing firm 23andMe files for Chapter 11 bankruptcy to sell itself

Genetic testing firm 23andMe filed for Chapter 11 bankruptcy in the U.S. on Sunday and said it was looking to sell itself.

AI 예측Beta

AI 추천

강세

업데이트 시간: 2025년 4월 28일 오전 09:47

약세중립강세

58.5% 신뢰도

리스크 & 트레이딩

리스크 수준4/5
고위험
적합 대상
가치성장공격적
트레이딩 가이드

진입점

$0.63

익절

$0.69

손절

$0.54

핵심 요소

현재 가격은 $0.65에서 MA(20)보다 7.5% 낮아 하락 모멘텀을 나타냅니다.
K 값 5.9은(는) D 값 8.4보다 낮고 20 미만이므로 과매도 상태를 시사합니다.
DMI는 약세 추세(ADX:26.6, +DI:24.2, -DI:53.1)를 보여 주의를 요합니다.
거래량은 평균(183,041)의 3.1배로 극도로 강력한 매수 압력을 나타냅니다.
MACD -0.0300이(가) 신호선 -0.0288 아래에 있어 약세 교차를 나타냅니다.

최신 정보 받기

가격 알림 설정, AI 분석 업데이트 및 실시간 시장 뉴스 받기